Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS

Handelsbanken Fonder AB raised its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 18.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 405,800 shares of the company’s stock after buying an additional 64,200 shares during the quarter. Handelsbanken Fonder AB owned about 0.36% of NewAmsterdam Pharma worth $11,541,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in NAMS. Jennison Associates LLC lifted its position in shares of NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Maverick Capital Ltd. lifted its holdings in NewAmsterdam Pharma by 178.8% in the 2nd quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock valued at $27,742,000 after purchasing an additional 982,405 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of NewAmsterdam Pharma by 47.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,458,897 shares of the company’s stock worth $26,421,000 after purchasing an additional 467,579 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 75,117 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $36.21, for a total transaction of $2,719,986.57. Following the completion of the sale, the chief accounting officer owned 15,000 shares of the company’s stock, valued at approximately $543,150. This represents a 83.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $35.31, for a total transaction of $1,605,934.11. Following the transaction, the insider directly owned 53,500 shares in the company, valued at approximately $1,889,085. This trade represents a 45.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 650,421 shares of company stock worth $22,417,631 in the last three months. 20.84% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Stock Up 3.4%

Shares of NAMS opened at $35.46 on Monday. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $42.00. The company’s fifty day moving average is $34.06 and its two-hundred day moving average is $33.06. The firm has a market cap of $4.08 billion, a PE ratio of -20.50 and a beta of 0.04.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. As a group, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. The Goldman Sachs Group increased their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Finally, Needham & Company LLC upped their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus price target of $46.55.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.